In ER-positive early-stage breast cancer, adjuvant endocrine therapy with ER receptor modulators such as tamoxifen or aromatase inhibitors substantially reduce the risk of loco-regional and distance recurrence [3]. The gene discussed is ESR1; the disease is breast carcinoma.